Journal article icon

Journal article

Lessons from IAVI-006, a phase I clinical trial to evaluate the safety and immunogenicity of the pTHr.HIVA DNA and MVA.HIVA vaccines in a prime-boost strategy to induce HIV-1 specific T-cell responses in healthy volunteers.

Abstract:

IAVI-006 was the first large randomised, double-blinded, placebo-controlled Phase I clinical trial to systematically investigate the prime-boost strategy for induction of HIV-1 specific CD8+ cytotoxic T-lymphocytes (CTL) in a factorial trial design using (i) priming with 0.5 mg or 2 mg of pTHr.HIVA DNA vaccine, followed by (ii) two booster vaccinations with 5 x 10(7) MVA.HIVA at weeks 8 and 12 (early boost) or weeks 20 and 24 (late boost). This study set the basis for later clinical trials an...

Expand abstract
Publication status:
Published

Actions


Access Document


Publisher copy:
10.1016/j.vaccine.2008.09.016

Authors


More by this author
Institution:
University of Oxford
Division:
MSD
Department:
NDM
Sub department:
Jenner Institute
Role:
Author
Journal:
Vaccine More from this journal
Volume:
26
Issue:
51
Pages:
6671-6677
Publication date:
2008-12-01
DOI:
EISSN:
1873-2518
ISSN:
0264-410X
Language:
English
Keywords:
Pubs id:
pubs:3216
UUID:
uuid:73a619b2-6c84-4f68-91f0-ee6de974023b
Local pid:
pubs:3216
Source identifiers:
3216
Deposit date:
2012-12-19

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP